MCK

Based on McKesson Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does McKesson do?

McKesson distributes pharmaceutical products — branded, generic, specialty, and biosimilar — to pharmacies, hospitals, and healthcare providers across the US and internationally. It also provides medical-surgical logistics, oncology practice support, and technology solutions that connect pharmacies, payers, and biopharma companies.

Does MCK pay dividends?

Yes, McKesson pays a regular dividend. The company's large-scale distribution operations generate recurring cash flows that support consistent dividend payments, though capital is also allocated toward share repurchases and reinvestment in technology platforms.

When does MCK report earnings?

McKesson reports on a quarterly cadence, in line with standard US-listed large-cap practice. For the exact schedule and most recent results, check McKesson's official investor relations page.

Is MCK a good stock to buy?

UQS Score rates MCK as Good overall. The Growth, Risk, and Valuation pillars all register positively, while Quality and Moat are Neutral — suggesting a stable but not structurally dominant business. Whether it fits your portfolio depends on your own investment criteria. View the full pillar breakdown on UQS Pro.

Is MCK overvalued?

The UQS Valuation pillar for MCK reads as Good, which suggests the stock is not obviously overpriced relative to its fundamentals. That said, valuation is one of five pillars — the complete picture requires reviewing Quality, Growth, Moat, and Risk together.

How does MCK compare to its competitors?

McKesson competes directly with Cencora and Cardinal Health in large-scale pharmaceutical distribution, and more broadly with Henry Schein in medical supply. All three peers operate in similarly margin-thin distribution environments. UQS Pro members can view side-by-side pillar comparisons for each competitor.

What is MCK's market cap bracket?

McKesson is classified as a large-cap company, reflecting its scale as one of the leading pharmaceutical distributors in the United States and a significant international operator.

Who founded McKesson?

McKesson was founded in 1833, making it one of the oldest companies in the US healthcare sector. Founding details are widely available through public historical records and McKesson's own corporate history resources.

Is MCK a long-term quality stock?

As a long-term quality indicator, MCK's Good UQS Score reflects a business with positive growth characteristics and a manageable risk profile. The Neutral Moat pillar is worth monitoring — durable competitive advantages are a key ingredient for long-term compounding. Pro members can track pillar changes over time.

What is the main competitive advantage of McKesson?

McKesson's primary advantage lies in its distribution scale and deeply embedded relationships across the pharmaceutical supply chain — from manufacturers to pharmacies and health systems. Its RxTS technology platform adds a layer of stickiness by integrating payers, providers, and biopharma partners into a single access ecosystem.

What sector does MCK belong to?

McKesson operates in the Healthcare sector, specifically within pharmaceutical and medical distribution. It sits at the infrastructure layer of the healthcare system rather than in drug development or direct patient care.

Is MCK a growth stock or value stock?

Based on UQS pillar labels, MCK leans toward a blend — the Growth pillar reads as Good, suggesting meaningful expansion, while the Valuation pillar also reads as Good rather than deep-value territory. It does not fit neatly into either pure category.

McKesson Corporation has average quality metrics, with room for improvement in margins or capital efficiency.

McKesson Corporation shows steady but unspectacular growth, typical for mature companies.

McKesson Corporation maintains a reasonable risk profile with manageable debt levels.

McKesson Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.

McKesson Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MCK.

The UQS (Unified Quality Score) for McKesson Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses McKesson Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether McKesson Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.